The immune system protects the body against foreign substances such as bacteria and viruses. Inflammation is the physical response to how the body naturally protects itself against infections and injury.

Janet van Adelsberg Janet Van Adelsberg, M.D. Senior Director, Clinical Sciences Immunology and Inflammation
Bola Akinlade Bola Akinlade, M.D., MBA, FACP Executive Director, Clinical Sciences

The word inflammation is derived from the Latin inflammare, to set on fire.  Inflammation is the physical response to how the body naturally protects itself against injury and infections, such as from bacteria and viruses.
But inflammation can also occur when the immune system inappropriately triggers an inflammatory response to the body’s own cells. Immune responses to the body’s own cells, called autoimmune disorders, involve overproduction of a class of immune system proteins called cytokines and a sub-class called interleukins. Regeneron scientists have developed several compounds that are designed to block the actions of interleukin molecules. Rilonacept is a fusion protein that binds Interleukin-1 (IL-1). Sarilumab, previously known as REGN88, is an antibody to the Interleukin 6 receptor. Dupilumab, previously known as REGN668, is an antibody to the receptors for Interleukin 4 and Interleukin 13.

ARCALYST® (rilonacept)

Rilonacept, known in scientific literature as IL-1 Trap, is an Interleukin-1 (IL-1) blocker. Rilonacept is a fusion protein that incorporates parts of the IL-1 receptor. It was designed by Regeneron scientists to attach to the pro-inflammatory protein interleukin-1 (IL-1) before IL-1 can bind to cell-surface receptors and generate signals that trigger inflammation.

Sarilumab/REGN88 (IL-6R Antibody)

An antibody against the interleukin-6 receptor in development for the treatment of rheumatoid arthritis and non-infectious uveitis in collaboration with Sanofi.

Dupilumab/REGN668 (IL-4R Antibody)

An antibody against the interleukin-4 receptor, through which both interleukin-4 and interleukin-13 signal, that is being evaluated in atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis in collaboration with Sanofi.

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Form content here please :)